Water → HCID 89251748, compound

HRID 1615403Notes

Reaction equation

[C:1]([O:5][C:6]([NH:8][CH:9]1[CH2:14][CH2:13][N:12]([C:15]2[CH:25]=[CH:24][C:18]([CH:19]=[CH:20][C:21]([OH:23])=O)=[CH:17][CH:16]=2)[CH2:11][CH2:10]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].C1C=CC2N(O)N=NC=2C=1.[NH:36]1[CH2:41][CH2:40][O:39][CH2:38][CH2:37]1.O>CN(C)C(=O)C>[C:1]([O:5][C:6]([NH:8][CH:9]1[CH2:14][CH2:13][N:12]([C:15]2[CH:16]=[CH:17][C:18]([CH:19]=[CH:20][C:21]([N:36]3[CH2:41][CH2:40][O:39][CH2:38][CH2:37]3)=[O:23])=[CH:24][CH:25]=2)[CH2:11][CH2:10]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]

Participants

Conditions

Temperature: 80 °C

Procedure

The 4-(4-tert-butoxycarbonylaminopiperidin-1-yl)-cinnamic acid (870 mg, 2.5 mmol) obtained in Example 11(1) was dissolved in N,N-dimethylacetamide (hereinafter referred to as DMA) (15 ml), and HOBt (423 mg, 2.8 mmol), WSCD (530 mg, 2.8 mmol), morpholine (241 mg, 2.8 mmol) were added thereto, followed by stirring at 80° C. for 16 hours. After cooling to room temperature, water was added to the mixture, and the precipitate was collected by filtration, thereby obtaining (3-(4-(4-tert-butoxycarbonylaminopiperidin-1-yl)-phenyl)-1-oxo-2-propen-1-yl)-morpholine (836 mg, 80%) as a white solid.

Workup

additionwere added
temperatureAfter cooling to room temperature
filtrationthe precipitate was collected by filtration

Sources & evidence

ORD record: ord-9d17d14eb87d4013824f5e80d976c4a9
Source dataset: uspto-grants-2014_07
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US08765750B2

Reaction notes

Loading…